Atlas Trials

Safety and Efficacy Study of QL0911 to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients

Clinical trial NCT07455006 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07455006
Sponsor
Qilu Pharmaceutical Co., Ltd.
Status
NOT_YET_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Thrombocytopenia, Immune
Start date
2026-04-20
Primary completion
2027-12-10
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.